Company Overview and News
2018-10-15 247wallst - 1
Stocks were indicated flat to marginally higher on Monday after last week’s sell-off was slightly tempered by Friday’s rally. While the all-time highs are still within striking distance, investors have seen lower upside from buying immediately after the big market pullbacks in 2018 than in prior years. Now those investors also have to consider how to position their investments for the rest of the year and into 2019.
WFCNP ARRS ACRX ATVI CLF DLPH AEO LULU ELAN MS WFC ABUS TRI MRO
Dublin and London - October 15, 2018 - Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based Oil & Gas Exploration Company, today provides an update on Frontier Exploration Licence ("FEL") 6/14 that contains the Newgrange Prospect. FEL 6/14 is operated by Providence Resources P.l.c., on behalf of its partner Sosina Exploration Limited (20%), collectively referred to as the Newgrange Partners, and is situated in c.
LNSTY MRO MIOI
Irina is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing on the oil and gas industry.
Is the bromance between President Donald Trump and Russian leader Vladimir Putin losing its passion? It seemed that way when Putin recently shared his thoughts about rising oil prices and oil stocks in general. The Russian strongman agreed with Trump that prices have skyrocketed. However, Putin placed blame on his administration for much of the pain.
CVX CTLR MRO EPD CLR OXY BXE EOG
Marathon Oil has built an attractive oil and gas production portfolio in four major U.S. basins: Bakken, Eagle Ford, STACK/SCOOP, and Permian. It also has some overseas operations.
STT MQBKY BOE WPXP WLL SM CTLR MCQEF AXAS MPC WPX EV EOG OAS WTI MRO CLR MQG
Reportedly, Marathon Oil Corporation (MRO - Free Report) recently kicked off the sale process of its North Sea oil and gas fields, in a bid to streamline portfolio and focus on U.S. shale production. The assets it intends to offload include its minority stakes in Foinaven fields in the west of Shetland area and interests in the Brae complex northeast of Aberdeen. According to banking sources, the divestment of these properties can fetch Marathon Oil around $200 million.
RDS.B RDS.A CSBR RYDBF MRO RDSB RDSA RYDAF
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
With today’s relatively generous $11.18 million federal estate tax exemption, estate planning is only a concern for the rich. Right? Wrong! In fact, regardless of your income or net worth, there’s one estate planning move you should probably make right now: check the beneficiary designations for your life insurance policies, bank accounts, brokerage firm accounts, retirement accounts, and so forth.
The initial response to news that a trade deal among North American countries had been made was bullish. It wasn’t meant to last though. By the time Monday’s closing bell rang, the S&P 500 intraday peak gain of nearly 0.8% had been pared back to a gain of only 0.36%. The Nasdaq Composite, meanwhile, was dragged all the way back into the red to log a 0.11% loss for the day.
WFC WFCNP GE GEC TWTR TSLA GNE MRO DHR
2018-10-01 seekingalpha - 2
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
APC APA WPXP DVN QEP PE CXO EPE RRL AR CRZO ROSEU REI GPOR JNEEP AMR MUR.WI MUR JAG ROSE XOG JGPK NBL WLL PDCE SRCI SM CTLR COG BCEI NFX RRS JONE WPX RGRLF EOG RRC OAS RGRYY LPI MRO CLR ROAN AEUA FANG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to MRO / Marathon Oil Corp. on message board site Silicon Investor.
as of ET